New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic
New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic Emerging research begins to identify neighborhood characteristics that could impact the incidence of and vulnerability to chronic disease |
[19-November-2019] |
PHILADELPHIA, Nov. 19, 2019 /PRNewswire/ -- More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of neighborhoods that may make people more – or less – prone to developing type 2 diabetes, paving the way for more targeted interventions to prevent disease. As part of Cities Changing Diabetes, a global program sponsored by Novo Nordisk involving 25 cities around the world, these groups will be working together to develop new ways to try to change the trajectory of diabetes in Philadelphia. The research is beginning to identify three distinct types of Philadelphia neighborhoods associated with the likelihood of residents developing type 2 diabetes:
Data gathered from the Brewerytown, Overbrook, and Richmond/New Kensington sections of the city were used to identify types and characteristics. These findings are based on extensive, prior data analyses and neighborhood dialogues, as part of Cities Changing Diabetes, a global program sponsored by Novo Nordisk that helps cities around the world understand their unique diabetes challenges, identify areas and populations at greatest risk, and design and implement targeted solutions. "By looking for certain neighborhood characteristics, we get a better understanding of the driving factors behind the rise of diabetes and obesity in urban settings, then share and apply that knowledge to build health improvement strategies for people to live healthier lives," said Stephen H. Linder, PhD, director of The Institute of Health Policy at UT Health School of Public Health and lead researcher for Cities Changing Diabetes in the US. The Philadelphia research was conducted by the Public Health Management Corporation (PHMC) and UTHealth School of Public Health which is the lead research partner for Cities Changing Diabetes in the US. The research was sponsored by Novo Nordisk. Philadelphia is now the second city in the US and the 25th city globally in the Cities Changing Diabetes network. Houston joined Cities Changing Diabetes five years ago and today has six initiatives that reach, empower and connect more than 75,000 Houstonians with diabetes prevention and management resources in their city. The Houston research identified behavioral/psychosocial characteristics of those who are more vulnerable to developing diabetes. The Philadelphia research builds on the approach used in Houston and takes it to the next level: the neighborhood. The research underscores the importance of community in addressing health and wellness and wellbeing. The Cities Changing Diabetes – Philadelphia coalition will use this information as it begins to develop and ultimately implement new programs to support diabetes prevention. "Diabetes doesn't have to be inevitable. But to change its trajectory, we need to prevent the disease in the first place. Medicines can't be the whole solution; we all need to look at the problem differently," said Doug Langa, executive vice president, North America Operations and President of Novo Nordisk Inc. "This can't be done alone, and no single organization can carry that burden. However, by working with like-minded stakeholders in cities like Philadelphia, we can take meaningful action, together." Diabetes in Philadelphia About Urban Diabetes and Cities Changing Diabetes A global program sponsored by Novo Nordisk, Cities Changing Diabetes is a private/public partnership that helps communities understand their unique diabetes challenges, identify areas and populations at greatest risk, and design and implement targeted solutions. It brings together medical and public health institutions, communities of faith, employers, insurers, and non-profit organizations. The program launched in the US in Houston five years ago, and today five initiatives have been sustained that reach, empower, and connect more than 75,000 Houstonians to improve diabetes prevention and management in their city. The program launched in Philadelphia in November 2019. For more information, follow #UrbanDiabetes and @citiesdiabetes. About Novo Nordisk 1 Data on file
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-cities-changing-diabetes-public-private-partnership-in-philadelphia-mobilizing-against-citys-diabetes-epidemic-300960364.html SOURCE Novo Nordisk | ||
Company Codes: NYSE:NVO |
© 2019 PR Newswire. All Rights Reserved.